MedTrace Logo

BN83495 in Prostate Cancer

NCT00790374 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-01-15

No results posted yet for this study

Summary

The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in patients with prostate cancer with disease progression while on androgen ablative therapy

Conditions

Interventions

DRUG

BN83495 (Cohort 1)

20 mg daily BN83495 for 28 days

DRUG

BN83495 (Cohort 2)

40 mg daily BN83495 for 28 days

DRUG

BN83495 (Cohort 3)

60 mg daily BN83495 for 28 days

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-10-31
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790374 on ClinicalTrials.gov